2023 World Conference on Lung Cancer (WCLC) - Extended Conference
Conference | English
Image For Activity Cover
Availability
On-Demand
3 Courses
Cost
Regular Member: $350.00
Member - Other: $250.00
Non-Member: $575.00
Member - Developing Country: $250.00
Non-Member - Developing Country: $300.00
Free: $0.00
Credit Offered
91 ACCME Credits
92 Certificate of Attendance Credits
Extended Conference: This extended, on-demand product is for purchase for individuals who did NOT attend the conference. 

Conference Attendees: If you attended the conference, click here to be redirected to the Live/Hybrid Attendee Access.
The IASLC World Conference on Lung Cancer is the largest international gathering in the field of lung cancer and thoracic oncology. The conference offers ground-breaking education in its wide-ranging and multidisciplinary content. In addition to traditional abstract presentations and lectures by world renowned speakers, the conference provided hands on workshops, interactive sessions, as well as several sessions dedicated to subspecialties like nurses, patients, and advocates. The IASLC World Conference on Lung Cancer is an excellent opportunity for initiating or strengthening ongoing co-operations and knowledge. The content provided during this Conference will benefit lung cancer patients around the globe. 

Sponsored by the International Association for the Study of Lung Cancer.
Live Activity Dates: September 9-12, 2023
Location: Singapore
Enduring Activity Launch Date: March 15, 2024
Enduring Activity Expiration Date: July 31, 2024
The IASLC 2023 World Conference on Lung Cancer is designed to meet the educational needs of researchers and healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses and physician assistants.
Upon completion of this activity, the participants should be able to: 
  • Examine scientific advances in thoracic cancer including the pathogenesis, biology, and mechanisms of drug interactions that can be used to make evidence-based diagnosis and treatment decisions.
  • Synthesize cutting edge research from clinical trials and translational studies conducted around the world to deepen knowledge within primary specialty area(s) and broaden knowledge of other specialties.
  • Support lung cancer prevention strategies including tobacco control, smoking cessation, reducing environmental risks, addressing the quality and value of healthcare, and implementing early screening.
  • Apply evidence-based recommendations and clinical practice guidelines to diagnose and manage patients.
  • Employ multidisciplinary teams to improve patient outcomes through patient-centered diagnostic, therapeutic and palliative care.
  • Support and empower patients to become active participants in their treatment.  
Program Co-Chairs:
  • Fiona Hegi-Johnson, MD, PhD
  • Pyng Lee, MD, PhD
  • Chee Lee, MD, PhD

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of the IASLC or any company that provided commercial support for this activity.

The information presented is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
If you need assistance with this actvity, please email: education@iaslc.org.
Powered By